Global Initiative for Psychedelic Science Economics (GIPSE)

Global Initiative for Psychedelic Science Economics (GIPSE)

Overview

GIPSE is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance clinical outcomes, increase efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Below is a list of current projects:

 

  • In collaboration with the Usona Institute, modeling the cost-effectiveness of psilocybin-assisted psychotherapy to treat major depressive disorders.
  • In collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), evaluating the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD.
  • In collaboration with Johns Hopkins University’s Center for Psychedelic and Consciousness Research, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.
  • Modeling the short and long-term epidemiological, economic, and budgetary impacts of scaled-up access to psychedelic therapies at the state and national level.

 

This two-page summary provides additional information on GIPSE’s mission and activities.

 

Advisory Council

UC collaborators

Elliot Marseille

CGHDDE Title
Director of GIPSE
Primary Affiliation
Principal of Health Strategies International

Stefano Bertozzi

CGHDDE Title
Professor of Health Policy and Management
Primary Affiliation
UC Berkeley School of Public Health

Jim Kahn

CGHDDE Title
Emeritus Professor of Health Policy, Epidemiology, and Global Health
Primary Affiliation
UCSF School of Medicine